- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07609524
Alleviation of Cardiometabolic Risk Factors Through Watermelon Rind
19. mai 2026 oppdatert av: Maria Aslam, University of Lahore
Alleviation of Cardiometabolic Risk Factors Through Watermelon (Citrullus Lanatus (Thunb.) Matsum. &Amp; Nakai) Rind-based Bread Among Cardiac Patients
To collect data, written consent was obtained from the hospital and university administration.
After receiving signed informed consent, the data was collected from cardiac patients.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The target population was adults between the ages of 35 and 65 years who were receiving outpatient care at a hospital or clinic with a diagnosis of either mild to moderate hypertension, mild to moderate alterations in lipid profile or pre-diabetes.
To select potential participants from the study population, subjects with a medical history of diabetes, measuring fasting blood glucose, lipid profile and blood pressure were screened.Following screening, participants were divided evenly into three groups: experimental group (1, 2) and one control group.
The participants were advised to take 2 slices of bread in breakfast.
Individualized plans were given according to their nutrient requirements.
A systematic communication plan was developed in order to follow up with participants on their daily consumption of the suggested watermelon rind-based bread through telephonic conversations.
For continuous assistance there was a WhatsApp group set up where members may ask issues and get help.
The follow up for patients were conducted every month; baseline and after 6 pre-treatments.
Appointments for follow-up exams were done after every 15 days in order to track developments, anthropometric measurements were calculated every follow up and modify the dosage as necessary.
The baseline and post study test was compared to test the hypothesis.
Studietype
Intervensjonell
Registrering (Faktiske)
120
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Punjab Province
-
Lahore, Punjab Province, Pakistan
- University of Lahore
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- The inclusion criterion was target adults with both gender aged 35-65 years. Adults with a diagnosis of mild to moderate hypertension Mild hypertension (140-159/90-99 mm Hg) Moderate hypertension (160-179/100-109 mm Hg) Adults having mild to moderate alterations in lipid profile Triglycerides: 150 to 499 mg/dL LDL-C levels: Mild Alteration (130 to 159 mg/dL) and Moderate Alteration (160 to 189 mg/dL) Adults with pre-diabetes (hbA1c= 5.6-6.4%)
Exclusion Criteria:
Any person allergic to wheat.
- Any person any person allergic to watermelon rind.
- Any adult having pancreatitis and hepatitis.
- Any adults having serious health conditions like cancer.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Control group on whole wheat bread
Participants were only subjected to use Wheat bread in breakfast.
|
Participants were advised to take Two slices of wheat bread in breakfast for the duration of 02 months.
|
|
Eksperimentell: G1 on 40% WRB
Participants were advised to take Watermelon rind-based bread (40% ) in breakfast for the duration of 02 months.
|
Participants were advised to take 2 slices of Watermelon rind-based bread in breakfast for the duration of 02 months.
|
|
Eksperimentell: G 2 on 60% WRB
Participants were advised to take Watermelon rind-based bread (60% ) in breakfast for the duration of 02 month.
|
Group 2: Participants were advised to take 2 slices of Watermelon rind-based bread in breakfast for the duration of 02 months.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Anthropometric Measurements
Tidsramme: 60 days
|
for body mass index weight in kg and height in meters squared, were used to calculate changes in body size.
|
60 days
|
|
Lipid Profile
Tidsramme: 60 days
|
Blood lipid profile was obtained using fasting blood samples to determine serum total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and triglycerides were monitored pre and post intervention.
|
60 days
|
|
Blood pressure
Tidsramme: 60 days
|
Blood pressure was checked using an automated sphygmomanometer.
Sitting blood pressure was measured in two ways; systolic blood pressure and diastolic blood pressure after 5 minutes rest.
For analysis, the average of the three readings were taken.
|
60 days
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Maria Aslam, University of Lahore
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
12. juni 2025
Primær fullføring (Faktiske)
19. august 2025
Studiet fullført (Faktiske)
20. september 2025
Datoer for studieregistrering
Først innsendt
8. mai 2026
Først innsendt som oppfylte QC-kriteriene
19. mai 2026
Først lagt ut (Faktiske)
27. mai 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
27. mai 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
19. mai 2026
Sist bekreftet
1. mai 2026
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- IRB-UOL-FAHS/837/2024
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .